High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia

Dysregulation of ID proteins is a frequent event in various human cancers and has a direct role in cancer initiation, maintenance, progression and drug resistance. Our previous study has revealed ID1 expression and its prognostic value in acute myeloid leukemia (AML). Herein, we further reported ID2 expression and its clinical significance in AML. Real-time quantitative PCR was performed to detect ID2 transcript level in bone marrow mononuclear cells of 145 de novo AML patients. ID2 expression was significantly up-regulated in AML patients compared with controls. ID2 overexpression occurred with the highest frequency in poor karyotype (10/17, 59%), lower in intermediate karyotype (35/83, 42%), and the lowest in favorable karyotype (7/40, 18%). Moreover, high ID2 expression correlated with lower complete remission (CR) rate, shorter overall survival, and acted as an independent prognostic biomarker in whole-cohort AML and non-M3-AML patients. Importantly, the prognostic value of ID2 expression in AML was validated by The Cancer Genome Atlas (TCGA) data. In the follow-up of patients, ID2 expression at CR phase was decreased than at the time of diagnosis, and was increased again at the time of relapse. These findings demonstrated that bone marrow ID2 overexpression was a frequent event in AML patients, and predicts poor chemotherapy response and prognosis.

[1]  Qin Chen,et al.  Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2011, PloS one.

[2]  G. Landberg,et al.  High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells , 2005, International journal of cancer.

[3]  J. Chen,et al.  Overexpressed DNA-binding protein inhibitor 2 as an unfavorable prognosis factor promotes cell proliferation in nasopharyngeal carcinoma. , 2012, Acta biochimica et biophysica Sinica.

[4]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[5]  F. Ferrara.  Unanswered questions in acute myeloid leukaemia. , 2004, The Lancet. Oncology.

[6]  Xin Hu,et al.  ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression , 2014, OncoTargets and therapy.

[7]  Qin Chen,et al.  IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome , 2012, Annals of Hematology.

[8]  A. Iavarone,et al.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness , 2014, Nature Reviews Cancer.

[9]  Qin Chen,et al.  Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. , 2015, International journal of clinical and experimental pathology.

[10]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  W. Jiang,et al.  The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer. , 2013, Anticancer research.

[13]  J. Qian,et al.  Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. , 2014, International journal of clinical and experimental pathology.

[14]  J. Qian,et al.  Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome , 2014, PloS one.

[15]  J. Qian,et al.  Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. , 2011, Clinical biochemistry.

[16]  J. Qian,et al.  The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia , 2016, Tumor Biology.

[17]  T. Somervaille,et al.  Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage. , 2016, Cancer cell.

[18]  J. Qian,et al.  CEBPA methylation and mutation in myelodysplastic syndrome , 2015, Medical Oncology.

[19]  J. Qian,et al.  Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies , 2017, Journal of cellular and molecular medicine.

[20]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[21]  J. Qian,et al.  RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. , 2013, Clinical biochemistry.

[22]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[23]  J. Cleveland,et al.  Id2 Is Dispensable for Myc-Induced Lymphomagenesis , 2004, Cancer Research.

[24]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[25]  J. Qian,et al.  Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis , 2016, Oncotarget.

[26]  Xinguang Yu,et al.  Downregulation of Id2 increases chemosensitivity of glioma , 2015, Tumor Biology.

[27]  K. Inokuchi.  [Prognostic factors of acute myeloid leukemia]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[28]  S. Wageningen,et al.  ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells , 2005, Leukemia.

[29]  M. Werner,et al.  ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes , 2013, Histochemistry and Cell Biology.

[30]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  Jessica E. Bolden,et al.  Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. , 2016, Cancer cell.

[33]  J. Qian,et al.  Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. , 2013, Leukemia research.

[34]  J. Qian,et al.  Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.